Loading...
Market
Will uniQure's AMT-130 therapy receive FDA approval for Huntington's disease by the end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
uniQure Stock Soars 27% on Positive Interim Data for AMT-130 Huntington’s Disease Therapy
Jul 9, 2024, 12:27 PM
uniQure has announced positive interim data from its Phase I/II trials of AMT-130, a one-time therapy for Huntington’s disease. The data demonstrated a statistically significant, dose-dependent, and durable evidence of therapeutic benefit, with patients receiving high-dose AMT-130 showing an 80% slowing of disease progression in the composite Unified Huntington’s Disease Rating Scale (cUHDRS). Significant improvements were also observed in neurofilament light chain (NFL) levels. The announcement has led to a 27% increase in uniQure's stock price. Despite the low numbers required given the risk of the intervention, this development marks a significant step towards the first disease-modifying treatment for Huntington’s disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Highly positive • 25%
Moderately positive • 25%
Neutral • 25%
Negative • 25%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%
